

Richard E Champlin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4461491/richard-e-champlin-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

534
papers

14,243
citations

56
h-index

110
g-index

557
ext. papers

17,360
ext. citations

3.9
avg, IF

5.94
L-index

#	Paper	IF	Citations
534	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , 2020 , 382, 545-553	59.2	652
533	Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. <i>Nature Medicine</i> , 2000 , 6, 1018-23	50.5	581
532	Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. <i>Blood</i> , 2001 , 97, 631-7	2.2	508
531	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015 , 126, 1033-40	2.2	431
530	Cord-blood engraftment with ex vivo mesenchymal-cell coculture. <i>New England Journal of Medicine</i> , 2012 , 367, 2305-15	59.2	377
529	Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. <i>PLoS ONE</i> , 2012 , 7, e30264	3.7	360
528	Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. <i>Blood</i> , 2004 , 104, 857-64	2.2	358
527	Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. <i>Cancer</i> , 2010 , 116, 5420-31	6.4	334
526	Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004 , 104, 865-72	2.2	320
525	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i> , 2008 , 111, 5530-6	2.2	261
524	Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. <i>Medicine (United States)</i> , 2006 , 85, 278-287	1.8	261
523	Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1863-1869	4.7	253
522	Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. <i>New England Journal of Medicine</i> , 2014 , 370, 1781-9	59.2	253
521	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. <i>Cancer Research</i> , 2015 , 75, 3505-18	10.1	246
520	Use of Leukemic Dendritic Cells for the Generation of Antileukemic Cellular Cytotoxicity Against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia. <i>Blood</i> , 1997 , 89, 1133-1142	2.2	220
519	Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E7788-E7797	11.5	213
518	Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1835-44	4.7	194

517	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016 , 127, 1656-65	2.2	184
516	High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. <i>Transplantation</i> , 2009 , 88, 1019-24	1.8	178
515	Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3497-505	2.2	175
514	Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1975-81	4.7	167
513	Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. <i>Cancer</i> , 2009 , 115, 1899-905	6.4	166
512	Phase 1 clinical trial using mblL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. <i>Blood</i> , 2017 , 130, 1857-1868	2.2	164
511	Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 145-54	4.7	164
510	The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. <i>Blood</i> , 2016 , 127, 260-7	2.2	158
509	Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. <i>Blood</i> , 2011 , 118, 5957-64	2.2	146
508	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 48-56	21.7	141
507	Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 672-84	4.7	136
506	Impact of high-dose chemotherapy on peripheral T-cell lymphomas. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3766-70	2.2	131
505	Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 10660-5	11.5	130
504	Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1262-73	4.7	130
503	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2015 , 121, 4158-64	6.4	129
502	Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. <i>PLoS ONE</i> , 2013 , 8, e76781	3.7	119
501	Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2240-7	2.2	115
500	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4167-75	2.2	111

499	Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1872-80	5.1	105
498	Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1392-8	4.7	101
497	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 177, 457-466	4.5	100
496	Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 454-62	4.7	100
495	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 432-40	4.7	95
494	The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. <i>Blood</i> , 2012 , 119, 2738-45; quiz 2969	2.2	95
493	Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 56-64	4.7	95
492	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 230-234	13.4	92
491	Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. <i>New England Journal of Medicine</i> , 2018 , 379, 1443-1451	59.2	87
490	Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. <i>Blood</i> , 2014 , 123, 3263-8	2.2	86
489	Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. <i>Clinical Cancer Research</i> , 2014 , 20, 5708-19	12.9	82
488	Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1290-1298	4.7	81
487	A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1555-62	4.7	80
486	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016 , 172, 392-400	4.5	79
485	Clofarabine + fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 893-900	4.7	76
484	CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2017-2024	4.7	75
483	Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016 , 122, 3316-3326	6.4	62
482	Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 584-92	4.7	62

481	Fifty years of melphalan use in hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 344-56	4.7	62
480	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017 , 123, 294-302	6.4	61
479	Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. <i>Blood</i> , 2021 , 137, 624-636	2.2	60
478	IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. <i>Blood</i> , 2016 , 128, 1346-61	2.2	56
477	Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. <i>Journal of Geriatric Oncology</i> , 2014 , 5, 422-30	3.6	49
476	Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. <i>British Journal of Haematology</i> , 1994 , 88, 72-8	4.5	49
475	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1247-1256	4.7	46
474	Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1059-64	4.7	46
473	Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 901-923	5.5	46
472	The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 319-26	2	45
471	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 726-733	4.7	45
470	Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1948-54	4.7	44
469	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 318-324	4.7	44
468	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. <i>British Journal of Haematology</i> , 2018 , 183, 578-587	4.5	44
467	Altered gene expression in busulfan-resistant human myeloid leukemia. <i>Leukemia Research</i> , 2008 , 32, 1684-97	2.7	43
466	Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 717-722	4.7	42
465	Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 180-4	4.7	42
464	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. <i>Blood Advances</i> , 2020 , 4, 5580-5588	7.8	42

463	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1218-1226	4.7	42
462	Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1514-1520	4.7	41
461	Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. <i>Journal of Clinical Oncology</i> , 2015 , 33, 364-9	2.2	41
460	Peripheral blood progenitor cell transplantation: a replacement for marrow auto- or allografts. <i>Stem Cells</i> , 1996 , 14, 185-95	5.8	41
459	A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 1992 , 81, 170-7	4.5	41
458	Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia.. <i>Blood</i> , 2004 , 104, 259-259	2.2	41
457	Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. <i>PLoS ONE</i> , 2016 , 11, e0159477	3.7	41
456	Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2016 , 173, 444-55	4.5	41
455	A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. <i>British Journal of Haematology</i> , 2000 , 109, 770-2	4.5	40
454	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. <i>Blood</i> , 2016 , 128, 297-312	2.2	40
453	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 47-53	4.7	39
452	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017 , 123, 459-467	6.4	39
451	Collection of peripheral blood stem cells from normal donors 60 years of age or older. <i>British Journal of Haematology</i> , 1997 , 97, 485-7	4.5	39
450	Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 110-117	6.6	38
449	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	37
448	The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. <i>Biochemical Pharmacology</i> , 2011 , 81, 222-32	6	37
447	5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. <i>Leukemia Research</i> , 2010 , 34, 364-72	7	37
446	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haematopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019 , 6, e266-e275	14.6	36

445	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1232-1236	4.7	36
444	Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. <i>PLoS ONE</i> , 2015 , 10, e0128151	3.7	36
443	Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. <i>British Journal of Haematology</i> , 1996 , 93, 940-2	4.5	34
442	Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 353-358	4.7	33
441	Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1618-25	4.7	33
440	Progress in haploidentical stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 372-80	4.7	33
439	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. <i>Cancer</i> , 2017 , 123, 2025-2034	6.4	32
438	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1914-20	4.7	32
437	Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. <i>Cytotherapy</i> , 2014 , 16, 84-9	4.8	32
436	Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 493-8	4.7	31
435	Allogeneic haematopoietic transplantation for Richter's syndrome. <i>British Journal of Haematology</i> , 2000 , 110, 897-9	4.5	31
434	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016 , 122, 2680-8	6.4	31
433	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. <i>American Journal of Hematology</i> , 2017 , 92, 331-337	7.1	29
432	Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. <i>British Journal of Haematology</i> , 1996 , 94, 155-8	4.5	29
431	Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1767-74	4.7	28
430	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. <i>Oncotarget</i> , 2015 , 6, 30487-99	3.3	28
429	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. <i>Haematologica</i> , 2015 , 100, 1361-70	6.6	27
428	Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1265-70	4.7	27

427	Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1714-20	4.7	26
426	Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 55-9	4.7	26
425	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 906-12	4.7	26
424	Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 713-9	4.7	26
423	Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. <i>Oncotarget</i> , 2018 , 9, 3908-3921	3.3	26
422	Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015 , 50, 939-946	4.4	25
421	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020 , 4, 1038-1050	7.8	25
420	Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>American Journal of Hematology</i> , 2012 , 87, 272-6	7.1	24
419	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020 , 7, e523-e533	14.6	24
418	Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. <i>Scientific Reports</i> , 2016 , 6, 21757	4.9	24
417	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019 , 3, 2836-2844	7.8	24
416	Hematologic malignancies and Li-Fraumeni syndrome. <i>Journal of Physical Education and Sports Management</i> , 2019 , 5,	2.8	22
415	Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1525-9	1.9	22
414	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 687-93	2	21
413	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020 , 4, 2073-2083	7.8	21
412	Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. <i>Molecular Imaging and Biology</i> , 2016 , 18, 838-848	3.8	21
411	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1405-1412	4.7	20
410	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2018 , 132, 971-971	2.2	20

409	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. <i>Cancer</i> , 2016 , 122, 3831-3837	6.4	20
408	Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. <i>Blood</i> , 2020 , 135, 449-452	2.2	20
407	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. <i>Cancer</i> , 2018 , 124, 2134-2141	6.4	19
406	Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 505-13	4.7	19
405	Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 297-300	4.2	19
404	Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 2166-2171	4.7	19
403	Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. <i>Current Oncology Reports</i> , 2000 , 2, 132-9	6.3	19
402	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. <i>JAMA Oncology</i> , 2020 , 6, 486-493	13.4	19
401	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. <i>Blood</i> , 2016 , 128, 2819-2823	2.2	19
400	Risk factors for falls in older patients with cancer. <i>BMJ Supportive and Palliative Care</i> , 2018 , 8, 34-37	2.2	18
399	Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2197-2203	4.7	18
398	The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, e1-5	2	18
397	Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1139-44	4.7	18
396	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2001 , 67, 227-33	7.1	18
395	Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1999 , 32, 279-88	1.9	18
394	Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1333-1337	4.7	18
393	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 601-606	4.4	18
392	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019 , 54, 839-848	4.4	18

391	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. <i>Cancer</i> , 2020 , 126, 2193-2205	6.4	17
390	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. <i>Cancer</i> , 2018 , 124, 2534-2540	6.4	17
389	NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. <i>Immunotherapy</i> , 2012 , 4, 305-13	3.8	17
388	Targeting the α_v integrin/TGF- β axis improves natural killer cell function against glioblastoma stem cells. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	17
387	Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1359-1366	4.7	16
386	A subset of virus-specific CD161 T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. <i>Blood</i> , 2017 , 129, 740-758	2.2	16
385	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. <i>European Journal of Haematology</i> , 2017 , 99, 532-535	3.8	16
384	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 285-292	4.7	16
383	Poor immune reconstitution is associated with symptomatic BK polyomavirus viremia in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2017 , 19, e12632	2.7	16
382	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. <i>American Journal of Hematology</i> , 2015 , 90, 1065-70	7.1	16
381	Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 457-62	2.2	16
380	A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1453-8	4.7	15
379	Control of nosocomial <i>Clostridium difficile</i> transmission in bone marrow transplant patients. <i>Infection Control and Hospital Epidemiology</i> , 2000 , 21, 226-8	2	15
378	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2159-2164	4.7	15
377	Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. <i>Oncology</i> , 2003 , 17, 94-100; discussion 103-7	1.8	15
376	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019 , 94, 1382-1387	7.1	14
375	Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. <i>Blood</i> , 2020 , 136, 1786-1789	2.2	14
374	Neurocognitive deficits in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 482-487	3.6	14

373	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2016 , 91, E442-7	7.1	14
372	Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2017 , 8, 1937	8.4	14
371	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018 , 5, e532-e542	14.6	14
370	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1607-15	1.9	13
369	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017 , 4, e283-e292	14.6	13
368	Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. <i>Experimental Hematology</i> , 2015 , 43, 448-61.e2	3.1	13
367	Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1013-1020	4.7	13
366	Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System. <i>Journal of Visualized Experiments</i> , 2015 ,	1.6	13
365	Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. <i>Blood</i> , 2018 , 132, 553-553	2.2	13
364	Is a matched unrelated donor search needed for all allogeneic transplant candidates?. <i>Blood Advances</i> , 2018 , 2, 2254-2261	7.8	13
363	Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. <i>Oncotarget</i> , 2018 , 9, 35611-35622	3.3	13
362	Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. <i>Blood Advances</i> , 2020 , 4, 3357-3367	7.8	13
361	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. <i>Blood Advances</i> , 2019 , 3, 1858-1867	7.8	13
360	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 581-587	4.7	12
359	Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34 Selected and Unmodified Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1079-1087	4.7	12
358	Massive Mobilization of AML Cells into Circulation by Disruption of Leukemia/Stroma Cell Interactions Using CXCR4 Antagonist AMD3100: First Evidence in Patients and Potential for Abolishing Bone Marrow Microenvironment-Mediated Resistance.. <i>Blood</i> , 2006 , 108, 568-568	2.2	12
357	Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. <i>Oncotarget</i> , 2016 , 7, 63829-63838	3.3	12
356	A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. <i>Blood Advances</i> , 2019 , 3, 4117-4130	7.8	12

355	Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. <i>EBioMedicine</i> , 2019 , 39, 612-620	8.8	12
354	Overall survival in older patients with cancer. <i>BMJ Supportive and Palliative Care</i> , 2020 , 10, 25-35	2.2	12
353	Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. <i>Blood</i> , 2018 , 131, 1248-1257	2.2	11
352	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 961-5	4.7	11
351	Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 226-231	4.7	11
350	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019 , 60, 442-452	1.9	11
349	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2006 , 108, 315-315	2.2	11
348	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2016 , 122, 3812-3820	6.4	11
347	Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. <i>Journal of Medical Virology</i> , 2020 , 92, 86-95	19.7	11
346	Prognostic Index for Critically Ill Allogeneic Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 991-996	4.7	10
345	Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study. <i>Transplant International</i> , 2018 , 31, 639-648	3	10
344	Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e41-e50	2	10
343	Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9 Suppl 3, S261-5		10
342	First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. <i>Blood</i> , 2013 , 122, 166-166	2.2	10
341	High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021 , 12, 675679	8.4	10
340	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. <i>Current Research in Translational Medicine</i> , 2019 , 67, 51-55	3.7	9
339	Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1687-95	4.7	9
338	Identification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors. <i>Journal of Clinical Apheresis</i> , 1998 , 13, 7-15	3.2	9

337	Graft-vs.-malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality. <i>Pediatric Transplantation</i> , 1999 , 3 Suppl 1, 52-8	1.8	9
336	Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1792-1800	4.7	9
335	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1039-1044	4.7	9
334	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 505-514	4.7	9
333	Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. <i>Frontiers in Immunology</i> , 2018 , 9, 2444	8.4	9
332	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2710-2719	2.2	9
331	Stem cell transplantation outcomes in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 366-371	3.7	8
330	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. <i>Cancer</i> , 2017 , 123, 3568-3575	6.4	8
329	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. <i>Cancer</i> , 2017 , 123, 2661-2670	6.4	8
328	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1439-1445	4.7	8
327	Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. <i>Cancer</i> , 2020 , 126, 2183-2192	6.4	8
326	Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 81-83	3.6	8
325	Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1723-4	4.7	8
324	Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitive Follicular Lymphoma (FL).. <i>Blood</i> , 2005 , 106, 48-48	2.2	8
323	Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1346-1354	11.6	8
322	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021 , 127, 2648-2656	6.4	8
321	Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. <i>Cell Reports</i> , 2021 , 36, 109432	10.6	8
320	Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 800-809	4.7	8

319	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1602-1609	4.7	7
318	Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. <i>Archives of Osteoporosis</i> , 2018 , 13, 38	2.9	7
317	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged \geq 5 years. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3536-3543	1.9	7
316	Ibrutinib Treatment Modulates T Cell Activation and Polarization in Immune Response. <i>Blood</i> , 2015 , 126, 3435-3435	2.2	7
315	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 665-671	4.7	7
314	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 Malignancies. <i>Clinical Cancer Research</i> , 2021 , 27, 3744-3756	12.9	7
313	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. <i>European Journal of Haematology</i> , 2016 , 97, 342-7	3.8	7
312	Next-Generation Sequencing of in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. <i>Frontiers in Oncology</i> , 2020 , 10, 582213	5.3	7
311	Decrease post-transplant relapse using donor-derived expanded NK-cells. <i>Leukemia</i> , 2021 ,	10.7	7
310	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. <i>Transfusion</i> , 2017 , 57, 1052-1057	2.9	6
309	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. <i>British Journal of Haematology</i> , 2017 , 178, 561-570	4.5	6
308	Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. <i>Haematologica</i> , 2021 , 106, 1988-1990	6.6	6
307	Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. <i>Journal of Clinical Apheresis</i> , 1999 , 14, 45-9	3.2	6
306	Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonist AMD3465 Enhances Chemotherapy-Induced Apoptosis in AML. <i>Blood</i> , 2005 , 106, 474-474	2.2	6
305	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia. <i>Blood</i> , 2007 , 110, 283-283	2.2	6
304	Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1245-1253	4.4	6
303	GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. <i>Frontiers in Immunology</i> , 2021 , 12, 626098	8.4	6
302	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. <i>Blood Advances</i> , 2021 , 5, 2799-2806	7.8	6

301	Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2021 ,	2.2	6
300	The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2705-2716	1.9	5
299	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. <i>British Journal of Haematology</i> , 2017 , 177, 567-577	4.5	5
298	Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2020 , 26, 2404-2410	12.0	5
297	Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. <i>Experimental Hematology</i> , 2016 , 44, 458-65	3.1	5
296	Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2644-52	1.9	5
295	Response: MHC class I chain-related gene A (MICA) in unrelated donor transplantation. <i>Blood</i> , 2009 , 114, 4754-4755	2.2	5
294	Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens. <i>Current Oncology Reports</i> , 2000 , 2, 182-91	6.3	5
293	Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. <i>Blood</i> , 2004 , 104, 2738-2738	2.2	5
292	The Role of Dasatinib in Patients with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Relapsing after Stem Cell Transplantation (SCT).. <i>Blood</i> , 2006 , 108, 4520-4520	2.2	5
291	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival.. <i>Blood</i> , 2007 , 110, 577-577	2.2	5
290	Zevalin /BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. <i>Blood</i> , 2007 , 110, 620-620	2.2	5
289	Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). <i>Blood</i> , 2013 , 122, 410-410	2.2	5
288	Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. <i>Blood</i> , 2013 , 122, 5356-5356	2.2	5
287	Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2015 , 126, 3155-3155	3.2	5
286	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. <i>Blood</i> , 2015 , 126, 854-854	2.2	5
285	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	5
284	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. <i>Blood Advances</i> , 2020 , 4, 4834-4837	7.8	5

283	Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. <i>Blood Advances</i> , 2020 , 4, 3474-3485	7.8	5
282	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 430.e1-430.e7		5
281	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Frontiers in Oncology</i> , 2021 , 11, 625707	5.3	5
280	Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. <i>American Journal of Hematology</i> , 2019 , 94, E176-E180	7.1	4
279	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1413-7	4.7	4
278	Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1529-1531	4.7	4
277	Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 1329-1333	4.7	4
276	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 36-42	2	4
275	Epigenetic modification enhances the cytotoxicity of busulfan and 4-hydroperoxycyclophosphamide in AML cells. <i>Experimental Hematology</i> , 2018 , 67, 49-59.e1	3.1	4
274	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. <i>Annals of Hematology</i> , 2019 , 98, 2233-2235	3	4
273	Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized by Thymic Regeneration Failure.. <i>Blood</i> , 2006 , 108, 312-312	2.2	4
272	Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.. <i>Blood</i> , 2006 , 108, 3668-3668	2.2	4
271	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. <i>Blood</i> , 2012 , 120, 4200-4200	2.2	4
270	How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. <i>Blood</i> , 2020 , 136, 2741-2753	2.2	4
269	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 642-649		4
268	Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1316-1324	4.4	4
267	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. <i>Haematologica</i> , 2019 , 104, e555-e557	6.6	3
266	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1340-1346	4.7	3

265	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. <i>Quality of Life Research</i> , 2018 , 27, 979-985	3.7	3
264	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. <i>Leukemia and Lymphoma</i> , 2018 , 59, 515-518	1.9	3
263	Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. <i>Leukemia Research</i> , 2016 , 47, 100-8	2.7	3
262	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. <i>European Journal of Haematology</i> , 2017 , 98, 263-268	3.8	3
261	Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11 Suppl 1, S96-100	2	3
260	Bone marrow transplantation for Hodgkin's disease--recent advances and current issues. <i>Leukemia and Lymphoma</i> , 1993 , 10 Suppl, 103-8	1.9	3
259	Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 1994 , 15, 85-90	1.9	3
258	Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. <i>Blood</i> , 2019 , 134, 700-700	2.2	3
257	Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD.. <i>Blood</i> , 2004 , 104, 1651-1651	2.2	3
256	IV Busulfan (Bu) with Fludarabine (Flu) or Cyclophosphamide (Cy) - Comparing Ablative Conditioning Regimens for Allogeneic Transplantation in AML/MDS.. <i>Blood</i> , 2004 , 104, 97-97	2.2	3
255	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A New Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 1159-1159	2.2	3
254	Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin's Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.. <i>Blood</i> , 2005 , 106, 44-44	2.2	3
253	Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.. <i>Blood</i> , 2006 , 108, 2460-2460	2.2	3
252	NK Cell Proliferation and Cytolytic Function Are Compromised In the Hypoxic Tumor Microenvironment. <i>Blood</i> , 2010 , 116, 4291-4291	2.2	3
251	Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial. <i>BoneKEy Reports</i> , 2016 , 5, 843		3
250	Inhibition of the β v integrin-TGF- β axis improves natural killer cell function against glioblastoma stem cells		3
249	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,. <i>Blood</i> , 2011 , 118, 4118-4118	2.2	3
248	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2811-2820	1.9	3

247	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 272.e1-272.e5		3
246	Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. <i>Frontiers in Immunology</i> , 2021 , 12, 631353	8.4	3
245	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019 , 25, 6781-6787	12.9	3
244	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019 , 94, E2-E5	7.1	3
243	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Cancer</i> , 2021 , 127, 1598-1605	6.4	3
242	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation 2021 , 9,		3
241	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2021 , 106, 3211-3214	6.6	3
240	Treatment of allosensitized patients receiving allogeneic transplantation. <i>Blood Advances</i> , 2021 , 5, 4031-4043	4.3	3
239	Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. <i>Pediatric Transplantation</i> , 2017 , 21, e12890	1.8	2
238	Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2019 , 142, 176-184	2.7	2
237	The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 1127	7.1	2
236	Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. <i>British Journal of Haematology</i> , 2018 , 183, 831-835	4.5	2
235	Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. <i>International Journal of Hematology</i> , 2009 , 90, 627-634	2.3	2
234	Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. <i>Blood</i> , 2020 , 136, 46-48	2.2	2
233	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.. <i>Blood</i> , 2004 , 104, 2301-2301	2.2	2
232	Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for Chronic Myelogenous Leukemia (CML).. <i>Blood</i> , 2004 , 104, 812-812	2.2	2
231	Prospective Feasibility Analysis of Reduced Intensity Conditioning Regimens (RIC) for Hematopoietic Stem Cell Transplantation (HSCT) in Elderly Patients with AML and MDS.. <i>Blood</i> , 2005 , 106, 2892-2892	2.2	2
230	Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.. <i>Blood</i> , 2005 , 106, 660-660	2.2	2

229	Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells.. <i>Blood</i> , 2006 , 108, 3654-3654	2.2	2
228	Sustained Engraftment Using Fludarabine, Melphalan and Thiotepa Conditioning for Haploidentical Stem Cell Transplantation.. <i>Blood</i> , 2007 , 110, 5081-5081	2.2	2
227	Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).. <i>Blood</i> , 2007 , 110, 948-948	2.2	2
226	Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2008 , 112, 2931-2931	2.2	2
225	IL-7 as a Membrane-Bound Molecule for the Costimulation of Tumor-Specific T Cells.. <i>Blood</i> , 2009 , 114, 3035-3035	2.2	2
224	A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010 , 116, 2358-2358	2.2	2
223	Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 1794-1794	2.2	2
222	Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 4321-4321	2.2	2
221	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. <i>Blood</i> , 2016 , 128, 3554-3554	2.2	2
220	Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy 2020 ,		2
219	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1746-1749	4.4	2
218	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. <i>Blood</i> , 2021 , 138, 1733-1739	2.2	2
217	Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2021 , 127, 3381-3389	6.4	2
216	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. <i>Blood Advances</i> , 2020 , 4, 1296-1306	7.8	2
215	Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. <i>Bone Marrow Transplantation</i> , 2021 , 56, 745-748	4.4	2
214	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 689-695		2
213	Cardiac Toxicity after Matched Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. <i>Blood Advances</i> , 2021 ,	7.8	2
212	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.. <i>Leukemia and Lymphoma</i> , 2022 , 1-9	1.9	2

211	Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1059-1063	4.7	1
210	Hematopoietic Cell Transplantation 2017 , 1-13		1
209	Haploidentical transplants for patients with graft failure after the first allograft. <i>American Journal of Hematology</i> , 2020 , 95, E267	7.1	1
208	Haploidentical transplants for patients with relapse after the first allograft. <i>American Journal of Hematology</i> , 2020 , 95, 1187	7.1	1
207	Hematopoietic stem cell transplantation 2016 , 440-451		1
206	Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 150	12.8	1
205	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. <i>British Journal of Haematology</i> , 2000 , 111, 18-29	4.5	1
204	Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. <i>Blood</i> , 2018 , 132, 1599-1599	2.2	1
203	Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkin Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response.. <i>Blood</i> , 2004 , 104, 1654-1654	2.2	1
202	Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.. <i>Blood</i> , 2004 , 104, 5239-5239	2.2	1
201	Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.. <i>Blood</i> , 2004 , 104, 734-734	2.2	1
200	RhG-CSF Mobilized and Apheresis-Collected Endothelial Progenitor Cells for Therapeutic Vasculogenesis.. <i>Blood</i> , 2005 , 106, 298-298	2.2	1
199	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3090-3090	2.2	1
198	Two-Year Follow-Up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin Lymphoma: Comparable Outcome with Matched Related and Unrelated Donors.. <i>Blood</i> , 2006 , 108, 3115-3115	2.2	1
197	HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT).. <i>Blood</i> , 2006 , 108, 3125-3125	2.2	1
196	Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantation (Auto) in First Remission.. <i>Blood</i> , 2008 , 112, 1141-1141	2.2	1
195	Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations. <i>Blood</i> , 2008 , 112, 3302-3302	2.2	1
194	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. <i>Blood</i> , 2008 , 112, 3320-3320	2.2	1

193	Impact of Pretransplant Cytogenetics and Marrow Remission Status on Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation Conditioned with Busulfan and Fludarabine. <i>Blood</i> , 2008 , 112, 341-341	2.2	1
192	Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009 , 114, 2267-2267	2.2	1
191	Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function.. <i>Blood</i> , 2009 , 114, 4097-4097	2.2	1
190	Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.. <i>Blood</i> , 2009 , 114, 868-868	2.2	1
189	Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. <i>Blood</i> , 2010 , 116, 2305-2305	2.2	1
188	Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes. <i>Blood</i> , 2010 , 116, 908-908	2.2	1
187	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 246-246	2.2	1
186	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 333-333	2.2	1
185	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.. <i>Blood</i> , 2012 , 120, 3094-3094	2.2	1
184	Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. <i>Blood</i> , 2013 , 122, 305-305	2.2	1
183	Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. <i>Blood</i> , 2016 , 128, 2916-2916	2.2	1
182	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016 , 128, 5884-5884	2.2	1
181	Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7047-7047	2.2	1
180	Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. <i>Blood</i> , 2021 , 138, 482-482	2.2	1
179	Double Loading of Dendritic Cell MHC Class I and MHC Class II with an AML Antigen Repertoire Enhances Primary and Secondary T-Cell Responses In Vitro.. <i>Blood</i> , 2004 , 104, 2529-2529	2.2	1
178	A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 3032-3032	2.2	1
177	Anti-Apoptotic Proteins, HSP90 and Activated STAT3 Contribute to Busulfan Resistance of Myeloid Leukemia Cells.. <i>Blood</i> , 2007 , 110, 3472-3472	2.2	1
176	Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.. <i>Blood</i> , 2007 , 110, 329-329	2.2	1

175	Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. <i>Blood</i> , 2008 , 112, 2999-2999	2.2	1
174	Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) from Donors Other Than Matched Siblings: A Prospective Evaluation of Hemorrhagic Cystitis (HC) Incidence. <i>Blood</i> , 2008 , 112, 50-50	2.2	1
173	Novel Influenza A (2009/H1N1) Infection In Patients with Hematological Malignancies During the 2009 Pandemic Outbreak: Early Antiviral Treatment Improves Survival. <i>Blood</i> , 2010 , 116, 1731-1731	2.2	1
172	Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant. <i>Blood</i> , 2010 , 116, 1722-1722	2.2	1
171	Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. <i>Haematologica</i> , 2021 , 106, 269-274	6.6	1
170	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2005-2012	4.4	1
169	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 404.e1-404.e5		1
168	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. <i>Leukemia</i> , 2021 ,	10.7	1
167	Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2021 , 96, E350-E353	7.1	1
166	Can we cure refractory Hodgkin's lymphoma with transplantation?. <i>Bone Marrow Transplantation</i> , 2021 , 56, 278-281	4.4	1
165	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2021 , 144, 74-81	2.7	1
164	Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking. <i>Cytotherapy</i> , 2021 , 23, 1029-1035	4.8	1
163	Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1347-1354	4.7	0
162	Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 29-30	2.2	0
161	Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 11-12	2.2	0
160	Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. <i>Blood</i> , 2020 , 136, 13-14	2.2	0
159	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 12	22.4	0
158	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2021 , 1-12	1.9	0

157	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. <i>Blood</i> , 2019 , 134, 257-257	2.2	○
156	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).. <i>Blood</i> , 2009 , 114, 2310-2310	2.2	○
155	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1077-1083	4.7	○
154	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 243.e1-243.e6		○
153	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. <i>American Journal of Hematology</i> , 2019 , 94, E72-E74	7.1	○
152	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 913.e1-913.e12		○
151	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <i>Clinical Cancer Research</i> , 2021 , 27, 5847-5856 ^{12.9}		○
150	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. <i>American Journal of Hematology</i> , 2021 , 96, E455-E457	7.1	○
149	Mismatch in SIRP β , a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2021 , 5, 3407-3417	7.8	○
148	Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2020 , 22, e13395	2.7	
147	Stem Cell Transplantation for Treatment of Malignancy 2018 , 201-214		
146	Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. <i>Blood</i> , 2020 , 136, 11-13	2.2	
145	Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial. <i>Blood</i> , 2020 , 136, 40-42	2.2	
144	PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. <i>Blood</i> , 2020 , 136, 6-7	2.2	
143	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020 , 136, 17-18	2.2	
142	Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. <i>Blood</i> , 2020 , 136, 9-11	2.2	
141	BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). <i>Blood</i> , 2020 , 136, 40-41	2.2	
140	Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade. <i>Blood</i> , 2020 , 136, 4-4	2.2	

139	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 18-19	2.2
138	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020 , 136, 22-22	2.2
137	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020 , 136, 17-18	2.2
136	A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab. <i>Blood</i> , 2020 , 136, 2-4	2.2
135	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020 , 136, 42-43	2.2
134	Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase II Study. <i>Blood</i> , 2020 , 136, 22-24	2.2
133	Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. <i>Blood</i> , 2020 , 136, 1-1	2.2
132	Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. <i>Blood</i> , 2020 , 136, 24-25	2.2
131	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 34-35	2.2
130	Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. <i>Blood</i> , 2020 , 136, 20-21	2.2
129	Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. <i>Blood</i> , 2020 , 136, 10-12	2.2
128	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 20-21	2.2
127	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. <i>Blood</i> , 2020 , 136, 10-11	2.2
126	Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting. <i>Blood</i> , 2020 , 136, 10-11	2.2
125	Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. <i>Blood</i> , 2020 , 136, 14-15	2.2
124	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 23-24	2.2
123	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. <i>Blood</i> , 2020 , 136, 27-28	2.2
122	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 40-41	2.2

121	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. <i>Blood</i> , 2020 , 136, 9-10	2.2
120	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. <i>Blood</i> , 2020 , 136, 39-40	2.2
119	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine + Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. <i>Blood</i> , 2020 , 136, 37-38	2.2
118	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 24-25	2.2
117	Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability.. <i>JMIR Formative Research</i> , 2022 , 6, e29393	2.5
116	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. <i>Blood</i> , 2021 , 138, 1802-1802	2.2
115	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021 , 138, 1779-1779	2.2
114	A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3941-3941	2.2
113	Impact of Vitamin D Deficiency on Survival for Patients Received Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT). <i>Blood</i> , 2021 , 138, 4853-4853	2.2
112	Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H.. <i>Blood</i> , 2004 , 104, 5132-5132	2.2
111	A Model to Predict Risk for Late Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation for Hematological Malignancies.. <i>Blood</i> , 2004 , 104, 2241-2241	2.2
110	Prevalence of Microbially Contaminated Hematopoietic Stem Cell Products.. <i>Blood</i> , 2004 , 104, 2228-2228.	2.2
109	Acute Myeloid Leukemia Lysate Loaded Dendritic Cells Exhibit Significant Phagocytic Function and Elicit Antigen-Specific Immune Response.. <i>Blood</i> , 2004 , 104, 2527-2527	2.2
108	Reduced-Intensity Conditioning Regimen with BEAM/Rituximab for Patients with Refractory Non-Hodgkin's Lymphomas.. <i>Blood</i> , 2004 , 104, 2315-2315	2.2
107	Impact of Prior Pregnancy on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 1638-1638	2.2
106	Allogeneic Stem Cell Transplantation with Reduced-Intensity, Fludarabine-Based Conditioning in Relapsed and Refractory Hodgkin's Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen on Survival.. <i>Blood</i> , 2004 , 104, 2135-2135	2.2
105	Effect of High-Dose Rituximab on Peripheral Blood Stem Cell Mobilization in Intermediate Grade Non-Hodgkin's Lymphomas.. <i>Blood</i> , 2004 , 104, 2877-2877	2.2
104	Retroviral Gene Transfer with Triple Genetic Reporter Genes into Human Cord Blood CD133+ Cells.. <i>Blood</i> , 2004 , 104, 5260-5260	2.2

103	A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen with T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).. <i>Blood</i> , 2004 , 104, 5184-5184	2.2
102	High Efficiency Transduction of Human Mesenchymal Stem Cells Using Retroviral Gene Transfer with Triple Reporter Genes.. <i>Blood</i> , 2004 , 104, 4258-4258	2.2
101	Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 3329-3329	2.2
100	Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M ² (MEL200).. <i>Blood</i> , 2005 , 106, 1177-1177	2.2
99	The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005 , 106, 1803-1803	2.2
98	Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 2923-2923	2.2
97	The Clinical Spectrum of Acute GVHD: Beyond Day 100.. <i>Blood</i> , 2005 , 106, 5377-5377	2.2
96	Cell-Autonomous Upregulation of Dendritic Cell Immunocompetence Is Antigen-Dependent.. <i>Blood</i> , 2005 , 106, 2230-2230	2.2
95	Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.. <i>Blood</i> , 2005 , 106, 1123-1123	2.2
94	Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005 , 106, 1135-1135	2.2
93	Treatment of Graft Failure with Fludarabine (Flu), Antithymocyte Globulin (ATG) and a Second Allogeneic Stem Cell Transplantation (SCT).. <i>Blood</i> , 2005 , 106, 2734-2734	2.2
92	Superior Acute Myeloid Leukemia-Specific T Cell Responses Using Dendritic Cells Pulsed with Apoptotic Bodies, vs. Tumor Lysates or mRNA.. <i>Blood</i> , 2005 , 106, 295-295	2.2
91	Distribution and Differentiation of Donor-Derived Bone Marrow Stem Cells in Various Areas of the Human Brain.. <i>Blood</i> , 2005 , 106, 1685-1685	2.2
90	Campath-1H Combined with Fludarabine/Cyclophosphamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.. <i>Blood</i> , 2005 , 106, 2302-2302	2.2
89	Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.. <i>Blood</i> , 2005 , 106, 2019-2019	2.2
88	Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006 , 108, 5316-5316 ^{2,2}	2.2
87	High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin Lymphoma (NHL) in Patients over 65 Years of Age.. <i>Blood</i> , 2006 , 108, 3059-3059	2.2
86	Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 5422-5422	2.2

85	ZAP-70 Status Does Not Predict Outcome after Nonmyeloablative Allogeneic Stem-Cell Transplantation (NST) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) That Fails To Respond to Conventional Chemoimmunotherapy.. <i>Blood</i> , 2006 , 108, 3028-3028	2.2
84	In Utero Is Superior to Ex Utero Cord Blood Collection.. <i>Blood</i> , 2006 , 108, 3645-3645	2.2
83	Does Polyoma (BK) Virus Contribute to Development of Hemorrhagic Cystitis (HC) in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (UD HSCT) Recipients? A Prospective Evaluation.. <i>Blood</i> , 2006 , 108, 5282-5282	2.2
82	Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.. <i>Blood</i> , 2006 , 108, 3101-3101	2.2
81	Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.. <i>Blood</i> , 2007 , 110, 5126-5126	2.2
80	Non-Integrating Gene Transfer To Redirect Specificity of Lymphocytes towards Pediatric CD19+ Malignancies. <i>Blood</i> , 2007 , 110, 3739-3739	2.2
79	Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin's Lymphomas (NHLs).. <i>Blood</i> , 2007 , 110, 1900-1900	2.2
78	Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes.. <i>Blood</i> , 2007 , 110, 2977-2977	2.2
77	Tacrolimus and Short-Term Methotrexate (mini-MTX) for Graft Versus Host Disease (GVHD) Prophylaxis after Unrelated Single Unit Cord Blood Transplant (CBT) in Pediatric Patients.. <i>Blood</i> , 2007 , 110, 5018-5018	2.2
76	Mismatches in Low Expression HLA Class II Loci and MIC-A in Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , 2007 , 110, 3050-3050	2.2
75	A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants.. <i>Blood</i> , 2007 , 110, 3051-3051	2.2
74	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. <i>Blood</i> , 2007 , 110, 48-48	2.2
73	Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation.. <i>Blood</i> , 2007 , 110, 3002-3002	2.2
72	CD19-Specific T Cells for Treatment of Pediatric Acute Lymphocytic Leukemia Using Sleeping Beauty Transposition.. <i>Blood</i> , 2007 , 110, 2820-2820	2.2
71	Jak2 Regulates Lyn Tyrosine Kinase through Interference with the SET/PP2A/Shp1 Pathway and Inhibition of Jak2 Induced Apoptosis in BCR-ABL+ Imatinib-Sensitive and Resistant CML Cells.. <i>Blood</i> , 2007 , 110, 3342-3342	2.2
70	Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).. <i>Blood</i> , 2007 , 110, 5015-5015	2.2
69	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. <i>Blood</i> , 2018 , 132, 4607-4607	2.2
68	Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following targeted small molecules inhibitors (SMIs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7550-7550	2.2

- 67 Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2019**, 134, 3596-3596 2.2
- 66 Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. *Blood*, **2019**, 134, 4598-4598 2.2
- 65 Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient. *Blood*, **2019**, 134, 1944-1944 2.2
- 64 Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).. *Journal of Clinical Oncology*, **2014**, 32, 4517-4517^{2,2}
- 63 Factors associated with bone fractures following hematopoietic stem cell transplantation.. *Journal of Clinical Oncology*, **2014**, 32, 9600-9600 2.2
- 62 Autologous stem cell transplantation in dialysis-dependent myeloma patients.. *Journal of Clinical Oncology*, **2014**, 32, 8601-8601 2.2
- 61 Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.. *Journal of Clinical Oncology*, **2014**, 32, 8538-8538 2.2
- 60 Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. *Blood*, **2016**, 128, 2270-2270 2.2
- 59 Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2016**, 128, 2276-2276 2.2
- 58 Allogeneic Stem Cell Transplantation Versus Medical Therapy in Patients with Advanced Myelofibrosis: Matched Survival Analysis and the Effect of JAK2 Inhibitor Therapy. *Blood*, **2016**, 128, 4687-4687^{2,2}
- 57 Haploidentical Donors in Addition to Transplantation in Chronic Phase Associate with Improved Gvhd-Free Relapse-Free Survival (GRFS) for Patients with Advanced CML. *Blood*, **2016**, 128, 4583-4583 2.2
- 56 Outcomes in Patients with Chronic Myelomonocytic Leukemia: Analysis of 279 Patients.. *Blood*, **2008**, 112, 3235-3235 2.2
- 55 Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.. *Blood*, **2008**, 112, 1128-1128 2.2
- 54 Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.. *Blood*, **2008**, 112, 1142-1142 2.2
- 53 High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma. *Blood*, **2008**, 112, 4452-4452 2.2
- 52 Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. *Blood*, **2008**, 112, 3298-3298 2.2
- 51 T Cells Demonstrate Enhanced Specificity for CD19+ Malignancies When Stimulated with IL-21.. *Blood*, **2008**, 112, 1539-1539 2.2
- 50 Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML. *Blood*, **2008**, 112, 3000-3000 2.2

49	Treatment of AML in First Remission (CR1) with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Unrelated Donors (UD).. <i>Blood, 2008, 112, 976-976</i>	2.2
48	Stem Cell Transplant (SCT) for Patients (pts) with Chronic Myeloid Leukemia (CML) Resistant to Tyrosine Kinase Inhibitors (TKI) with BCR-ABL Kinase Domain (KD) Mutation T315I.. <i>Blood, 2008, 112, 2120-2120</i>	2.2
47	Upregulation of XAF1 by 5-Aza-2'-Deoxycytidine Sensitizes Busulfan-Resistant Human CML Cells; Implications for Pretransplant Conditioning Therapy in Myeloid Leukemia. <i>Blood, 2008, 112, 5046-5046</i>	2.2
46	Donor-Recipient Mismatches in MHC Class I Chain-Related Gene a (MICA) in Unrelated Donor (UD) Transplantation. <i>Blood, 2008, 112, 58-58</i>	2.2
45	Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia. <i>Blood, 2008, 112, 2905-2905</i>	2.2
44	Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. <i>Blood, 2008, 112, 3306-3306</i>	2.2
43	Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS.. <i>Blood, 2008, 112, 2227-2227</i>	2.2
42	Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). <i>Blood, 2008, 112, 4326-4326</i>	2.2
41	Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. <i>Blood, 2008, 112, 3297-3297</i>	2.2
40	Regulatory and Naïve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML. <i>Blood, 2008, 112, 719-719</i>	2.2
39	Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. <i>Blood, 2008, 112, 799-799</i>	2.2
38	Enrichment of Mononuclear Cells From Cryopreserved Cord Blood Units Using the Purecell Select System.. <i>Blood, 2009, 114, 2159-2159</i>	2.2
37	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. <i>Blood, 2009, 114, 3213-3213</i>	2.2
36	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.. <i>Blood, 2009, 114, 2309-2309</i>	2.2
35	Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation.. <i>Blood, 2009, 114, 4354-4354</i>	2.2
34	Sustained Ex Vivo Expansion of Human Peripheral Blood NK Cells Using Artificial APCs Bearing Membrane-Bound IL-21.. <i>Blood, 2009, 114, 3030-3030</i>	2.2
33	Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma.. <i>Blood, 2009, 114, 1227-1227</i>	2.2
32	Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). <i>Blood, 2010, 116, 2548-2548</i>	2.2

- 31 Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. *Blood*, **2010**, 116, 3510-3510 2.2
- 30 Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma.. *Blood*, **2010**, 116, 4569-4569 2.2
- 29 Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS.. *Blood*, **2010**, 116, 3446-3446 2.2
- 28 Leuprolide Acetate (GnRH Agonist) to Enhance Immune Function Post-Autologous Hematopoietic Stem Cell Transplantation (HSCT). *Blood*, **2010**, 116, 4292-4292 2.2
- 27 Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. *Blood*, **2010**, 116, 2453-2453 2.2
- 26 Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. *Blood*, **2010**, 116, 2100-2100 2.2
- 25 Effect of Stem Cell Source From Unrelated Donors on Transplant Outcomes In Severe Aplastic Anemia (SAA): a Comparison of Unrelated Bone Marrow (BM) and Peripheral Blood Progenitor Cells (PBPC). *Blood*, **2010**, 116, 531-531 2.2
- 24 Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older.. *Blood*, **2010**, 116, 4576-4576 2.2
- 23 Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. *Blood*, **2010**, 116, 2341-2341 2.2
- 22 Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant.. *Blood*, **2010**, 116, 1322-1322 2.2
- 21 Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study. *Blood*, **2010**, 116, 489-489 2.2
- 20 Concordance Between the Serum Levels of Interleukin-6, MicroRNA-21, and the Severity of Subjective Symptoms of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. *Blood*, **2010**, 116, 2953-2953 2.2
- 19 Targeting Leukemias by CD123 Specific Chimeric Antigen Receptor. *Blood*, **2011**, 118, 1908-1908 2.2
- 18 12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,. *Blood*, **2011**, 118, 4138-4138 2.2
- 17 Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts,. *Blood*, **2011**, 118, 4047-4047 2.2
- 16 Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. *Blood*, **2011**, 118, 3106-3106 2.2
- 15 Nonmyeloablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. *Blood*, **2011**, 118, 894-894 2.2
- 14 Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. *Blood*, **2011**, 118, 2006-2006 2.2

- 13 Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma.. *Blood*, **2011**, 118, 4135-4135 2.2
- 12 Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. *Blood*, **2012**, 120, 3115-3115 2.2
- 11 Reconstitution of Lymphocyte Subsets and Outcomes After Matched and Mismatched Hematopoietic Stem-Cell Transplantation. *Blood*, **2012**, 120, 4485-4485 2.2
- 10 Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. *Blood*, **2012**, 120, 3129-3129 2.2
- 9 Relevance and Factors Predicting for Early Lymphocyte Recovery After Allogeneic Bone Marrow Stem Cell Transplantation (BMT).. *Blood*, **2012**, 120, 3053-3053 2.2
- 8 Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience. *Blood*, **2012**, 120, 1977-1977 2.2
- 7 Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2013**, 31, 7010-7010 2.2
- 6 Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). *Blood*, **2013**, 122, 2142-2142 2.2
- 5 Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. *Blood*, **2013**, 122, 3358-3358 2.2
- 4 Phosphorylation Of GSK3 β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. *Blood*, **2013**, 122, 2551-2551 2.2
- 3 Is There An Expiration Date For Cord Blood Units In Storage?. *Blood*, **2013**, 122, 299-299 2.2
- 2 Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation. *Blood*, **2013**, 122, 2880-2880 2.2
- 1 A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. *Transplantation and Cellular Therapy*, **2021**, 27, 837.e1-837.e10